<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105854">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01849562</url>
  </required_header>
  <id_info>
    <org_study_id>ACH102-007</org_study_id>
    <nct_id>NCT01849562</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy of 12-weeks of Sovaprevir, ACH-3102 and Ribavirin in Treatment-naive GT-1 HCV Subjects</brief_title>
  <official_title>A Phase 2a Trial to Evaluate the Safety, Tolerability and Efficacy of 12 Weeks of Sovaprevir, ACH-0143102 and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotype-1 Viral Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achillion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achillion Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>New Zealand: Medsafe</authority>
    <authority>Australia: Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability and efficacy of 12 weeks of treatment with sovaprevir,
      ACH-3102 and ribavirin in GT1, treatment-naive, HCV subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Determine the Incidence of Sustained Virologic Response 4 weeks (SVR4) after the completion of treatment</measure>
    <time_frame>Four weeks after the completion of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>HCV RNA less than the limit of quantification (&lt;LOQ), in subjects who received active treatment (sovaprevir and ACH-0143102 in combination with ribavirin) as compared to those who received placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety measured via adverse events; laboratory tests, ECGs, vital signs and physical exams.</measure>
    <time_frame>Through 12 weeks of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events will be assessed for their severity and association with study drug; physical exams, laboratory values, ECGs and vital signs will be assessed and summarized as changes from baseline values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence of sustained virologic response at 8 weeks (SVR8) following the completion of dosing</measure>
    <time_frame>8 weeks following completion of dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the incidence of SVR8 weeks after the completion of dosing, reported as HCV RNA less than the limit of quantification (&lt;LOQ) in subjects who received active treatment (sovaprevir and ACH-0143102 in combination with ribavirin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence of sustained virologic response at 12 weeks (SVR12) following the completion of dosing</measure>
    <time_frame>12 weeks following completion of dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the incidence of SVR12 weeks after the completion of dosing, reported as HCV RNA less than the limit of quantification (&lt;LOQ) in subjects who received active treatment (sovaprevir and ACH-0143102 in combination with ribavirin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence of sustained virologic response at 24 weeks (SVR24) following the completion of dosing</measure>
    <time_frame>24 weeks following completion of dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the incidence of SVR24 weeks after the completion of dosing, reported as HCV RNA less than the limit of quantification (&lt;LOQ) in subjects who received active treatment (sovaprevir and ACH-0143102 in combination with ribavirin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence of complete early virologic response (cEVR) at the end of the 12-week treatment period</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the incidence of complete early virologic response (cEVR) at the end of the 12-week treatment period reported as HCV RNA less than the limit of quantification (&lt;LOQ) target not detected in subjects who received active treatment (sovaprevir and ACH-0143102 in combination with ribavirin) as compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence of rapid virologic response (RVR)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the incidence of rapid virologic response (RVR) defined as HCV RNA less than the limit of quantification (&lt;LOQ) target not detected at week 4 in subjects receiving active treatment (sovaprevir and ACH-0143102 in combination with ribavirin) as compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence of extended rapid virologic response (eRVR)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the incidence of extended rapid virologic response (eRVR) defined as HCV RNA less than the limit of quantification (&lt;LOQ) target not detected at weeks 4 and 12 in subjects receiving active treatment (sovaprevir and ACH-0143102 in combination with ribavirin) as compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic analysis of trough samples analyzed for concentrations of sovaprevir, ACH-3102 and ribavirin from baseline through week 20.</measure>
    <time_frame>Week 20</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the PK/PD relationship between the combination treatment regimen (sovaprevir, ACH-0143102 and ribavirin) and virologic response</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>sovaprevir 200 mg/ACH-3102 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sovaprevir 200 mg capsule QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg capsule QD + weight-based ribavirin BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sovaprevir 400 mg/ACH-3102 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sovaprevir 400 mg capsule QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg capsule QD + weight-based ribavirin BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for sovaprevir capsule QD + placebo for ACH-3102 150 mg loading dose on Day 1 followed by 50 mg capsule QD + placebo for weight-based ribavirin BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sovaprevir</intervention_name>
    <description>NS3/4A protease inhibitor</description>
    <arm_group_label>sovaprevir 200 mg/ACH-3102 50 mg</arm_group_label>
    <arm_group_label>sovaprevir 400 mg/ACH-3102 50 mg</arm_group_label>
    <other_name>ACH-0141625</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-3102</intervention_name>
    <description>NS5A inhibitor</description>
    <arm_group_label>sovaprevir 200 mg/ACH-3102 50 mg</arm_group_label>
    <arm_group_label>sovaprevir 400 mg/ACH-3102 50 mg</arm_group_label>
    <other_name>ACH-0143102</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>tablets</description>
    <arm_group_label>sovaprevir 200 mg/ACH-3102 50 mg</arm_group_label>
    <arm_group_label>sovaprevir 400 mg/ACH-3102 50 mg</arm_group_label>
    <other_name>Ribasphere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HCV infection documented by one of the following:

          -  HCV genotype 1

          -  HCV RNA &gt; 10,000 IU/mL at screening.

          -  Signed and dated written informed consent form.

          -  Willing to participate in all study activities and all study requirements (including
             effective contraception) during study period.

          -  Treatment na√Øve subjects defined as subjects who have never received pegylated
             interferon, RBV, or a direct-acting anti-viral agent for the treatment of chronic HCV
             infection.

          -  A liver biopsy within the last 3 years without evidence of cirrhosis

        Exclusion Criteria:

          -  Body Mass Index (BMI) &gt; 36.0

          -  Pregnant or nursing (lactating) females, confirmed by a positive human chorionic
             gonadotropin (HCG) laboratory test or females contemplating pregnancy

          -  Participation in any interventional clinical trial within 35 days prior to first
             study medication dose administration on Day 1

          -  Known HIV-1 or HIV-2 infection/serology and/or positive Hepatitis B Surface Antigen
             (HBsAg)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 18, 2013</lastchanged_date>
  <firstreceived_date>April 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>Genotype 1</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Hepatitis, viral, human</keyword>
  <keyword>ribavirin</keyword>
  <keyword>antiviral agents</keyword>
  <keyword>anti-infective agents</keyword>
  <keyword>protease inhibitors</keyword>
  <keyword>NS5a inhibitors</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
